<DOC>
	<DOCNO>NCT01916447</DOCNO>
	<brief_summary>The purpose study investigate safety determine maximum tolerate dose TAS-102 administered combination CPT-11 patient advance gastrointestinal tumor .</brief_summary>
	<brief_title>A Phase I Study TAS-102 Patients With Advanced Gastrointestinal Tumors .</brief_title>
	<detailed_description>This open-label , non-randomized , dose-escalation , Phase 1 study TAS-102 administer combination CPT-11 . The study conduct 2 part : Dose Escalation Phase ( Part 1 ) determine maximum tolerate dose Expansion Phase ( Part 2 ) evaluate safety , pharmacokinetics , preliminary efficacy maximum tolerate dose . Patients assign sequential dose-level cohort cohort correspond pre-specified dose TAS-102 CPT-11 combination . Escalation subsequent dose level occur previous dose level determine safe .</detailed_description>
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Trifluridine</mesh_term>
	<criteria>1 . Has provide write informed consent 2 . Has advance gastrointestinal tumor refractory least 1 chemotherapy 3 . ECOG performance status 0 1 4 . Is able take medication orally 5 . Has adequate organ function ( bone marrow , kidney liver ) 6 . Women childbearing potential must negative pregnancy test must agree adequate birth control conception possible . Males must agree adequate birth control . 1 . Has certain recent treatment e.g . major surgery , extend field radiation , anticancer therapy , receive investigational agent , within specified time frame prior study drug administration 2 . Presence serious illness medical condition ( ) e.g . brain metastasis , systemic infection , heart failure 3 . Has unresolved toxicity great equal CTCAE Grade 1 attribute prior therapy 4 . Known sensitivity TAS102 , CPT11 , Bevacizumab , components 5 . Is pregnant lactate female 6 . Has either partial total gastrectomy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Angiogenesis Inhibitor</keyword>
	<keyword>Monoclonal Antibody</keyword>
	<keyword>Vascular Endothelial Growth Factor A ( VEGF-A )</keyword>
</DOC>